ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Omeprazole

Also written as “Atazanavir/Ritonavir+Omeprazole”, “omeprazole” and “Omeprazole 20 mg”.

Its studies are mostly in Gastroesophageal Reflux · Neoplasms · Laryngopharyngeal Reflux · Heartburn · HIV Infections, led by 13 companies.

Drug pageOmeprazole: every studyMany companies study it; this page follows only the 32 they lead. All 164 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 18, 200832 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only90 open or runningphase 4since Mar 18, 2008Nov 20, 2005none ahead
Bayerits history only40 open or runningphase 4since Apr 4, 2012May 2, 2008none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 8, 2010Jan 8, 2010none ahead
Boehringer Ingelheimits history only30 open or runningphase 1since Sep 30, 2014Sep 30, 2014none ahead
GlaxoSmithKlineits history only20 open or runningphase 1since Mar 1, 2007Mar 1, 2007none ahead
Procter and Gambleits history only20 open or runningphase 4since Dec 15, 2008Dec 15, 2008none ahead
Sanofiits history only20 open or runningphase 3since Sep 2, 2009Sep 2, 2009none ahead
AbbVie10 open or runningphase 3since Apr 29, 2008Apr 29, 2008none ahead
Ascension Healthits history only10 open or runningphase 4since Jan 25, 2013Jan 25, 2013none ahead
Nekkar Lab Srlits history only11 open or runningno phasesince Oct 14, 2019Oct 14, 2019none ahead

Also a collaborator on its studies: PT Pharma Metric Labs, Parexel, Medpace, Syreon, Bausch Health Companies, Ferring Pharmaceuticals and Tanabe Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2008First study: phase 3 study in Helicobacter InfectionsFirst studyNCT00669955 · 440 enrolled · United Kingdom

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

The one study AbbVie leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00669955Helicobacter Infections · United Kingdom3CompletedJul 2009440

How it is read

Names in the registry

  • “Omeprazole”, 30 entries
  • “Atazanavir/Ritonavir+Omeprazole”, 4 entries
  • “omeprazole”, 3 entries
  • “Omeprazole 20 mg”, 2 entries
  • “Omeprazole/sodium bicarbonate”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.